Annovis Bio
General Information | |
Business: |
Annovis is a clinical stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease in Down syndrome (AD-DS), Alzheimer’s disease (AD) and Parkinson’s disease (PD). We have an ongoing Phase 2a proof-of-concept study in AD patients and have planned to commence a second Phase 2a study in PD patients. We are developing our lead compound, ANVS-401, for chronic neurodegenerative diseases, such as AD-DS, AD and PD. In a number of studies, ANVS-401 inhibited the synthesis of neurotoxic proteins—APP/Ab (APP), tau/phospho-tau (tau) and a-Synuclein (a-SYN)—that are the main cause of neurodegeneration. High levels of neurotoxic proteins lead to impaired axonal transport, which is responsible for the communication between and within nerve cells. |
Industry: | PHARMACEUTICAL PREPARATIONS |
Employees: | 2 |
Founded: | 2008 |
Contact Information | |
Address | 1055 Westlakes Drive, Suite 300, Berwyn, PA 19312, US |
Phone Number | (610) 727-3913 |
Web Address | http://www.annovisbio.com |
View Prospectus: | Annovis Bio |
Financial Information | |
Market Cap | $41.5mil |
Revenues | $0 mil (last 12 months) |
Net Income | $-0.95 mil (last 12 months) |
IPO Profile | |
Symbol | ANVS |
Exchange | NYSE - American |
Shares (millions): | 2.0 |
Price range | $6.00 - $6.00 |
Est. $ Volume | $12.0 mil |
Manager / Joint Managers | ThinkEquity (a division of Fordham Financial Management, Inc. ) |
CO-Managers | - |
Expected To Trade: | 1/29/2020 |
Status: | Priced |
Quiet Period Expiration Date: | Available only to Subscribers |
Lock-Up Period Expiration Date: | Available only to Subscribers |
SCOOP Rating | Available only to Subscribers |
Rating Change | Available only to Subscribers |